Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00930930 · ClinicalTrials.gov registry record · Phase 2
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
- 8
- Study locations
NCT00930930: Completed Phase 2 study of Breast Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
NCT00930930 is a Phase 2 study of Breast Cancer that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 145 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00930930, a Phase 2 study of Breast Cancer, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
- 8
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving chemotherapy together with everolimus before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether cisplatin and paclitaxel are more effective when given together with or without everolimus in treating patients with breast cancer. PURPOSE: This randomized phase II trial is studying how well cisplatin and paclitaxel work when given together with or without everolimus in treating patients with stage II or stage III breast cancer.
Primary Outcome
Pathological complete response is defined as no residual tumor on histopathological analysis of both breast and axillary contents.
Conditions Studied
Interventions
- OTHER placebo
- DRUG cisplatin
- DRUG paclitaxel
- DRUG everolimus
- PROCEDURE Venous blood draw
Study Locations (8)
Tennessee
- Vanderbilt-Ingram Cancer Center - Cool Springs - Nashville
- MBCCOP - Meharry Medical College - Nashville - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Alabama
- University of Alabama - Birmingham
Mississippi
- University of Mississippi Medical Center Research Institute - Jackson
Pennsylvania
- Hershey Medical Center - Hershey
Texas
- The Methodist Hospital Research Institute - Houston
Virginia
- University of Virginia Health Sciences Center - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2009-06 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
What the finished NCT00930930 record still lists
NCT00930930 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which placebo is the first listed.
NCT00930930 lists 8 locations in 6 states (Tennessee, Alabama, Mississippi).
Frequently Asked Questions
What is clinical trial NCT00930930 about?
NCT00930930 is a clinical study titled "Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and b...
What is the current status of trial NCT00930930?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2009-06. Estimated completion is 2014-10.
What conditions does trial NCT00930930 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00930930?
The interventions under investigation include: placebo (OTHER), cisplatin (DRUG), paclitaxel (DRUG), everolimus (DRUG), Venous blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT00930930?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00930930 being conducted?
This trial has 8 study locations across Alabama, Mississippi, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00930930's enrollment target sits among peer trials
145 456th of 1224 higher than 766 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia